Mesoblast Limited (NASDAQ:MESO) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, September 15th.
Several other equities research analysts have also recently issued reports on the stock. CIBC began coverage on shares of Mesoblast Limited in a research note on Thursday, August 31st. They set an “outperform” rating and a $16.00 target price on the stock. Oppenheimer Holdings, Inc. began coverage on shares of Mesoblast Limited in a research note on Thursday, August 31st. They set an “outperform” rating and a $16.00 target price on the stock. Maxim Group set a $14.00 target price on shares of Mesoblast Limited and gave the stock a “buy” rating in a research note on Wednesday, August 30th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 target price on shares of Mesoblast Limited in a research note on Wednesday, August 30th. Finally, BidaskClub lowered Mesoblast Limited from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $13.64.
Shares of Mesoblast Limited (NASDAQ:MESO) traded up 0.18% during midday trading on Friday, reaching $5.47. 5,302 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $6.46 and its 200-day moving average is $8.22. The stock’s market cap is $464.64 million. Mesoblast Limited has a 12-month low of $4.01 and a 12-month high of $12.50.
ILLEGAL ACTIVITY NOTICE: This report was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/09/22/mesoblast-limited-meso-lowered-to-sell-at-valuengine.html.
An institutional investor recently raised its position in Mesoblast Limited stock. Princeton Capital Management Inc. boosted its stake in Mesoblast Limited (NASDAQ:MESO) by 15.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 155,700 shares of the company’s stock after buying an additional 20,945 shares during the period. Princeton Capital Management Inc. owned approximately 0.20% of Mesoblast Limited worth $1,398,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.95% of the company’s stock.
Mesoblast Limited Company Profile
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.